Prevalence of COVID-19 among blood donors
The Jordan University of Science and Technology experience

Ziad Elnasser, MD, PhD, Haneen Obeidat, MSc,
Zouhair Amarin, MD, MSc, FMGEMS, FRCOG, MHPE, FFPH, Nasr Alrabadi, MD, PhD,
Abdullah Jaradat, Du’a Alomarat, MSc, Mo’ath BaniSaleem, Randa Almomani, MSc

Abstract
The corona virus disease-19 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, had health and economic results that profoundly affected communities worldwide. Investigating the seroprevalence of SARS-CoV-2 in blood donors is of a significant clinical and scientific value as it adds to knowledge about local herd immunity levels. To study the prevalence of SARS-CoV-2 infection among blood donors at a tertiary referral hospital in the north of Jordan.

This is a prospective study that included all blood donors between September 2020 and March 2021. Donors’ IgG antibodies were qualitatively immunoassayed to determine the antibody status against SARS-CoV-2. The Elecsys Anti-SARS-CoV-2 technique was utilized.

One thousand samples were tested by total antibody against SARS-CoV-2. The median age was 29 years, 96.7% were males. The seroprevalence was 14.5%, and 80% of the positive participants did not report previous COVID-19 infection. The seroprevalence of COVID-19 antibodies was less among smokers and those with an O blood group and higher among donors with an AB blood group.

The prevalence of COVID-19 among healthy young blood donors at a tertiary teaching health facility in the north of Jordan was 14.5%. Smokers and those with an O blood group were less likely to be seropositive, as opposed to donors with an AB blood group.

Abbreviations: COVID-19 = corona virus disease-19, SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Keywords: ABO blood groups, blood donors, COVID-19, SARS-CoV-2 antibodies, seroprevalence

1. Introduction
A new pandemic of the viral disease “corona virus disease-19 (COVID-19)” started in Wuhan, capital of Hubei province in China late in 2019. It has affected millions of people worldwide with a very high death toll.[1] This infection may manifest with minor symptoms, or alternatively may lead to a problematic differential diagnosis. Real-time reverse transcriptase-polymerase chain reaction techniques are necessary.[2–4]

The detection of the IgM and IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may play an important role in epidemiological studies.[5] Screening of blood donors for antibodies serves as an indicator of the prevalence of infection in communities.

The first case reported for COVID-19 in Jordan was identified in March 2020 in a patient who came from Italy. This was followed by a steady climb in the total number of diagnosed cases.[6] Hundreds of cases were admitted to King Abdullah University Hospital. This hospital is affiliated to the Jordan University of Science and Technology, and is the only hospital that deals with COVID-19 cases in the north of Jordan.

At the time of the study, the national seroprevalence rates ranged between 0% and 27.4%,[7,8] and between 0% and 34.5% worldwide.[7–12]

The objectives of this study were to determine the prevalence of COVID-19 antibodies at a blood banking facility that is affiliated to a tertiary university referral hospital, and to describe some characteristics of those that test positive.
2. Methods

This is a prospective epidemiological study of COVID-19 seroprevalence among blood donors that complied with the blood donation protocol. The study took place between September 2020 and January 2021 at a tertiary-care university hospital that serves a population of 1.2 million in the north of Jordan.

The study was conducted at the height of the pandemic, where severe social restrictions and lockdown measures were in force in the governorate of Irbid, in the north of Jordan, a small country with an approximate population of 10 million. This led to a strict access to the hospital with a resultant decrease in the overall number of blood donors.

Participation in the study was voluntary. Written consent was obtained. Participants’ age, gender, level of education, and addresses were recorded.

Serum samples were collected. Recombinant nucleocapsid protein against SARS-CoV-2 technique (Elecsys Anti-SARS-CoV-2, Roche Diagnostics GmbH, Mannheim) was utilized for qualitative determination of antibodies that mainly included IgG,[13] using Cobas 6000 at the biochemistry laboratory. The ABO blood group was reported for each participant.

For statistical analysis, the SPSS version 20 software was utilized. Chi-square test was used for categorical variables. Binary regression model was used to predict risk of SARS-CoV-2 infection. P value of <.05 was considered significant.

An institutional review board approval was obtained for this study.

3. Results

The characteristics of 1000 random blood donors that participated in this study are summarized in Table 1. The vast majority of participants were males, where 14.5% of the total donors were seropositive. There was no statistically significant association in relation to participants’ gender, age, residency, occupation, material status, or educational level. However, smokers had a significantly lower rate of seroprevalence (Table 1).

Table 2

The ABO blood group distribution in blood donors, stratified by the presence of anti-SARS-CoV-2 antibodies.

| Absent (%) | Present (%) | Total (%) | P value |
|------------|-------------|-----------|---------|
| A          | 290 (33.9)  | 53 (36.6) | 343 (34.3) | .537 |
| B          | 169 (19.8)  | 33 (22.8) | 202 (20.2) | .407 |
| O          | 336 (39.3)  | 41 (28.3) | 377 (37.7) | .011 |
| AB         | 60 (7)      | 18 (12.4) | 78 (7.8)   | .025 |
| Rh Positive| 749 (87.6)  | 128 (88.3) | 877 (87.7) | .819 |
| Rh Negative| 106 (12.4)  | 17 (11.7)  | 123 (12.3) | .819 |

SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

The ABO blood group and Rh (D) factor distribution in blood donors, stratified by the presence of anti-SARS-CoV-2 antibodies are presented in Table 2.

Binary regression test for statistically significant variables showed that the seroprevalence of COVID-19 antibodies was less among smokers and those with an O blood group, and higher among donors with an AB blood group. There was no statistically significant difference in Rh grouping. The A and B blood groups had a high Odd Ratio, but without statistically significant difference (Table 3).

4. Discussion

The north of Jordan witnessed the earliest reported cases of COVID-19 pandemic. COVID-19 antibodies seroprevalence was 14.5% after 4 months of lockdown. In a study from Amman, the capital of Jordan, there was 0 prevalence for SARS-CoV-2 antibodies at the beginning of the pandemic.[17] A later study in early 2021 of healthy blood donors from the same center reported a 27.4% seroprevalence.[8] This dramatic increase is echoed by the results of this study which was conducted between the above 2 studies.

Results of studies from Italy, China, Brazil, US, Saudi Arabia, England, Scotland, and Spain gave different seroprevalence rates that were related to different factors such as sample size, targeted population, study period, diagnostic techniques, social distancing, lockdown procedures, and the order of the infection wave.[14–21]

Most studies show different associations between blood ABO-Rh grouping and COVID-19 infections. Some studies found that the A-type blood group was associated with the highest risk of infection,[22–23] while in this study the AB-type was associated with the highest infection rate. The findings of a study from Saudi

| Smoking | Reference | P value |
|---------|-----------|---------|
| Yes     | 0.657     | 0.518 (0.356–0.754) | .001 |
| No      | Reference |

| Blood group | OR (95% CI) | P value |
|-------------|-------------|---------|
| A           | 0.419       | 1.520 (0.990–2.359) | .062 |
| B           | 0.421       | 1.524 (0.926–2.507) | .097 |
| AB          | 0.891       | 2.439 (1.308–4.548) | .005 |

OR = Odd Ratio, CI = Class Interval, SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2. Reference group for smoking were non-smoker.

Reference group for smoking were non-smoker.

Reference group for blood groups were O blood group participants.
Arabia\[18\] and another from the US\[24\] are similar to those of this study.

Although it seems like a paradox, data of hospitalized and non-hospitalized patients, confirm a non-association between smoking and COVID-19 disease. This study found that smoking is less likely to develop COVID-19 disease. This is in concordance with systematic reviews and meta-analyses evaluating the relationship to develop COVID-19 disease. This study found that smoking is less likely hospitalized patients, con

To our knowledge this is the first study of COVID-19 prevalence in blood donors in the north of Jordan. One of the limitations of this study is the fact that most of the blood donors were males of young age. Further studies are needed to include other age groups in different communities.

Acknowledgment

The authors wish to thank Dr Suhaib Khatieb, Wessam Sheyab, Nuha Obaid, Hussam Refay, and Suliman Hussinat for their help and support.

Author contributions

Conceptualization: Ziad Elnasser, Haneen Obeidat.

Data curation: Haneen Obeidat, Abdullah Jaradat, Du’a Alomarat, Mo’ath BaniSalem, Randa Almomanii.

Formal analysis: Haneen Obeidat.

Funding acquisition: Ziad Elnasser.

Investigation: Ziad Elnasser, Haneen Obeidat.

Methodology: Haneen Obeidat, Abdullah Jaradat, Du’a Alomarat, Mo’ath BaniSalem, Randa Almomanii.

Project administration: Ziad Elnasser, Haneen Obeidat.

Software: Haneen Obeidat, Abdullah Jaradat, Mo’ath BaniSalem.

Supervision: Ziad Elnasser, Haneen Obeidat.

Validation: Ziad Elnasser, Haneen Obeidat, Zouhair Amarin.

Visualization: Ziad Elnasser, Haneen Obeidat.

Writing – original draft: Haneen Obeidat.

Writing – review & editing: Ziad Elnasser, Haneen Obeidat, Zouhair Amarin, Nasr Alrabadi.

References

[1] European Centre for Disease Prevention and Control. Covid-19. Available at: https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases. Accessed February 11, 2021.

[2] Wu X, Cai Y, Huang X, et al. Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia. China Emerg Infect Dis 2020;26:1324–32.

[3] Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science 2020;368:489–93.

[4] Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020;7:4. https://doi.org/10.1186/s40779-020-0233-6.

[5] Yong SEF, Anderson DE, Wei WE, et al. Connecting clusters of COVID-19: an epidemiological and serological investigation. Lancet Infect Dis 2020;20:809–15.

[6] https://corona.moh.gov.jo/ar.

[7] Sughayer MA, Mansour A, Al Nairat A, Souan L, Ghanem M, Siag M. Covid-19 seroprevalence rate in healthy blood donors from a community under strict lockdown measures. MedRxiv. 2020.

[8] Sughayer MA, Mansour A, Al Nairat A, Souan L, Ghanem M, Siag M. Dramatic rise of seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: the evolution of a pandemic. MedRxiv. 2021. https://doi.org/10.1101/2021.03.02.21232448.

[9] Kar SS, Sarkar S, Muraili S, Dhopakpar R, Joseph NM, Aggarwal R. Prevalence and time trend of SARS-CoV-2 infection in Puducherry, India, August-October 2020. Emerg Infect Dis 2021;27:666–9.

[10] Alamjany TA, El-Kafrawy AA, Al-Ghamdi AA, et al. Lack of antibodies to SARS-CoV-2 among blood donors during COVID-19 lockdown: a study from Saudi Arabia. Healthcare (Basel) 2021;9:51. doi.org/10.3390/healthcare9010051.

[11] Slot E, Hogema BM, Reusken CBM, et al. Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands. Nat Commun 2020;11:5744. doi.org/10.1038/s41467-020-19481-7.

[12] Xu R, Huang J, Duan C, et al. Low prevalence of antibodies against SARS-CoV-2 among voluntary blood donors in Guangzhou, China. J Med Virol 2021;93:1743–7.

[13] Roche Diagnostics. Elecsys Anti-SARS-CoV-2. 2020. Available at: https://diagnostics.roche.com/global/en/products/params/elecsys-anti-sars-cov-2.html. Accessed October 10, 2020.

[14] Aljanobi GA, Alhajjaj AH, Alkhabbaz FL, Mansour Al-Jishi J. The prevalence of antibodies to SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroprevalence study, England. EClinicalMedicine 2020;28:100597. doi.org/10.1016/j.eclinm.2020.100597.

[15] Bendavid E, Mulaney B, Sood N, et al. Covid-19 antibody seroprevalence in healthy blood donors during the COVID-19 Milan outbreak. MedRxiv. 2020. doi.org/10.1101/2020.05.11.20098442.

[16] Chang L, Hou W, Zhao L, et al. The prevalence of antibodies to SARS-CoV-2 among blood donors in China. Nat Commun 2021;12:1–10.

[17] Amorim Filho L, Sewarcwald CL, de Oliveira Garcia Mateos S, et al. Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil. Rev Saude Publica 2020;54:69. doi.org/10.11606/es.1518-8787.2020054002643.

[18] Aljanobi GA, Alhajjaj AH, Alkhabbaz FL, Mansour Al-Jishi J. The relationship between ABO blood group type and the COVID-19 susceptibility in Qatar Central Hospital, Eastern Province, Saudi Arabia: a retrospective cohort study. Open J Intern Med 2020;10:232–8.

[19] Ladhani SN, Jeffery-Smith A, Patel M, et al. High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19: prospective cohort study, England. EClinicalMedicine 2020;28:100597. doi.org/10.1016/j.eclinm.2020.100597.

[20] Thompson CP, Grayson NE, Paton RS, et al. Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. Euro Surveill 2020;25:2000685.

[21] Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020;396:335–44.

[22] Zhao J, Yang Y, Huang H, et al. Relationship between the ABO blood group and the COVID-19 susceptibility. Clin Infect Dis 2021;73:328–31.

[23] Gallian P, Pastirino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. Antiviral Res 2020;181:104880. doi.org/10.1016/j.antiviral.2020.104880.

[24] Vassallo RR, Bravo MD, Dumont LJ, Hazegh K, Kamel H. Seroprevalence of anti-SARS-CoV-2 among blood donors in China. Nat Commun 2021;9:31.

[25] Alsandary H, Diab M, Al LOGIN H, et al. Prevalence of antibodies to SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study, England. EClinicalMedicine 2020;28:100597. doi.org/10.1016/j.eclinm.2020.100597.

[26] Aljanobi GA, Alhajjaj AH, Alkhabbaz FL, Mansour Al-Jishi J. The prevalence of antibodies to SARS-CoV-2 among blood donors in China. Nat Commun 2021;9:31.

[27] Xu R, Huang J, Duan C, et al. Low prevalence of antibodies against SARS-CoV-2 among voluntary blood donors in Guangzhou, China. J Med Virol 2021;93:1743–7.